Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UC Davis.

Efficient Induction of Haploid Plants

Researchers at the University of California, Davis have developed an efficient technique for the haploid induction of plants.

Device and Method to Assess Ocular Surface Health

Researchers at the University of California, Davis have developed a diagnostic device and method to determine ocular surface health.

Measurement of Nanoscale Physical Enhancement by Materials under X-ray Irradiation

Researchers at the University of California, Davis have developed a method to study interactions of high density nanoparticles in solution with high spatial resolution.

Combined Individual Nanomaterial Enhancements for Total X-Ray Enhancement

Researchers at the University of California, Davis have developed a method to combine individual nanomaterial enhancements to achieve greater X-ray enhancement.

Novel Inhibitors of Mitochondrial Electron Transport

Researchers at the University of California, Davis have discovered a class of compounds that both bind to a unique newly-discovered binding site in respiratory complex III and act as inhibitors of electron transport for use as mitochondrial anti-cancer drugs.

Modulation Of p53 as a Cancer Therapeutic Target

Researchers at the University of California, Davis have designed peptides and oligonucleotide sequences to enhance p53 expression.

Method for Optimizing System Efficiency and Demand Response Performance of Variable-Speed/Variable-Capacity Furnaces, Heat Pumps and Air Conditioners

Researchers at the University of California, Davis have developed a methodology which maximizes the overall efficiency of variable-speed heat pumps, furnaces and air conditioner systems with minimal hardware changes.

Anti-Androgens for the Treatment of Chemotherapy Resistant Prostate Cancers

Researchers at the University of California, Davis have discovered a special class of androgen inhibitors for the treatment of chemotherapeutic prostate resistant cancers.